Ventyx Biosciences Inc (VTYX) - Total Liabilities
Based on the latest financial reports, Ventyx Biosciences Inc (VTYX) has total liabilities worth $20.10 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Ventyx Biosciences Inc net asset momentum to track the company's year-over-year net asset growth rate.
Ventyx Biosciences Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Ventyx Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data.
Ventyx Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Ventyx Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Scandi Standard publ AB
ST:SCST
|
Sweden | Skr4.96 Billion |
|
HyUnion Holding Co Ltd
SHE:002537
|
China | CN¥4.80 Billion |
|
Bonheur
OL:BONHR
|
Norway | Nkr15.88 Billion |
|
KPC Pharmaceuticals Inc
SHG:600422
|
China | CN¥5.15 Billion |
|
Techwing Inc
KQ:089030
|
Korea | ₩421.58 Billion |
|
Shandong Laiwu Jinlei Wind Power Technology Co Ltd
SHE:300443
|
China | CN¥652.73 Million |
|
NB Bancorp, Inc. Common Stock
NASDAQ:NBBK
|
USA | $6.15 Billion |
|
Jiangsu Maixinlin Aviation Science & Technology Corp. A
SHG:688685
|
China | CN¥2.11 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Ventyx Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Ventyx Biosciences Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ventyx Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ventyx Biosciences Inc (2019–2024)
The table below shows the annual total liabilities of Ventyx Biosciences Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $22.52 Million | -33.32% |
| 2023-12-31 | $33.77 Million | +92.92% |
| 2022-12-31 | $17.50 Million | +42.51% |
| 2021-12-31 | $12.28 Million | -60.25% |
| 2020-12-31 | $30.90 Million | +590.17% |
| 2019-12-31 | $4.48 Million | -- |
About Ventyx Biosciences Inc
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a sele… Read more